Stopping the Phase II trial of its ADC product IMGN901 on patients with non-small-cell lung cancer is most probably a temporary setback, which we believe would have no negative long-term impact on ImmunoGen’s (IMGN) success and growth. The failure of the drug has nothing to do with ImmunoGen’s TAP technology that has been validated through the approval of HER2 positive breast cancer ADC product Kadcyla® and through many years of experimentation.
Finding that the addition of IMGN901 to etoposide/carboplatin (E/C) was unlikely to demonstrate a sufficient improvement in progression-free survival compared to E/C alone to justify continuation of the trial, the firm was advised to halt the lung cancer clinical trials with the combination.
As ImmunoGen stated in its press release, infection-related toxicity is, indeed, a recognized risk in SCLC trials, including trials with etoposide/carboplatin. With regard to IMGN901 as a single agent, was given to 198 patients with only one incidence of infection-related death deemed possibly drug related.
Logically speaking, one setback among more than 16 studies is not unusual, or a precedent. From what we experienced and heard until now, we do not expect long-term impact on ImmunoGen from this setback.
Kadcyla's sales for HER2 breast cancer will continue to climb and Kadcyla is expected to move up as first line treatment at the end of next year if not before – a move expected to increase Kadcyla’s sales, which are expected to exceed those of Roche’s HER2 breast cancer blockbuster Herceptin’s sales
With regard to ImmunoGen’s wholly owned products, it is true that the firm might have lost one, but it has recently initiated trials with three wholly owned ADC compounds, including IMGN853 for ovarian, endometrial, and other cancers that highly express folate receptor α; IMGN529 for non-Hodgkin lymphoma; and IMGN289 for lung, head and neck, and other cancers that highly express EGFR.
"Investors will get a first look at data from an early study of Geron's (GERN_) imetelstat in myelofibrosis on Thursday when the American Society of Hematology makes research abstracts to its December annual meeting available online. " COME ON
"At this risk of overselling, these imetelstat data are super important because they will either justify Geron's incredible 180% stock surge over the past two months or make a fool of those who believed (naively) Geron might be capable of reversing more than two decades of drug development futility. " PLAY DOWN
"Imetelstat, a telomerase inhibitor, is Geron's last chance. " FEED NEGATIVITY - PAN
"Yet there is legitimate buzz surrounding imetelstat going into Thursday's ASH abstract release because the drug may have legitimate disease-modifying potential in bone marrow cancers like myelofibrosis" CYA
Almost like he wants people to sell, so he can buy?
Buying on the dips, this is a steal at 13.
So glad they finally stopped IMGN901, time to shift money into the newer technologies being developed like EGFR-Targeting ADC, IMGN289 and others in the pipeline !!!